Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer
暂无分享,去创建一个
[1] A. Slomiany,et al. Glycosulfatase activity of H. pylori toward human gastric mucin: effect of sucralfate. , 1992, The American journal of gastroenterology.
[2] S. Truelove,et al. The histological diagnosis of chronic gastritis in fibreoptic gastroscope biopsy specimens , 1972, Journal of clinical pathology.
[3] E. Kuipers,et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. , 1996, The New England journal of medicine.
[4] D. Forman,et al. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high risk groups. , 1996, British Journal of Cancer.
[5] M. Blaser,et al. Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro , 1995, Infection and immunity.
[6] K. Haruma,et al. Helicobacter pylori infection is the major risk factor for atrophic gastritis. , 1995, The American journal of gastroenterology.
[7] R. Puntoni,et al. Atrophic gastritis and intestinal metaplasia in asymptomatic Hungarian and Italian populations. , 1980, Endoscopy.
[8] F. Davis,et al. A cohort study of stomach cancer risk in men after gastric surgery for benign disease. , 1993, Journal of the National Cancer Institute.
[9] L. Fändriks,et al. A mechanism by which Helicobacter pylori infection of the antrum contributes to the development of duodenal ulcer. , 1996, Gastroenterology.
[10] M. Stolte,et al. Lymphoid follicles in antral mucosa: immune response to Campylobacter pylori? , 1989, Journal of clinical pathology.
[11] S. Tominaga,et al. A Prospective Study of Atrophic Gastritis and Stomach Cancer Risk , 1992, Japanese journal of cancer research : Gann.
[12] T. Karttunen,et al. Helicobacter pylori in dyspeptic patients: quantitative association with severity of gastritis, intragastric pH, and serum gastrin concentration. , 1991, Scandinavian journal of gastroenterology. Supplement.
[13] M. Vessey,et al. Postmarketing surveillance of the safety of cimetidine: 10 year mortality report. , 1992, Gut.
[14] M. Mäki,et al. Helicobacter pylori gastritis in dyspeptic children. A long-term follow-up after treatment with colloidal bismuth subcitrate and tinidazole. , 1994, Scandinavian journal of gastroenterology.
[15] J. Papadimitriou,et al. Endoscopic, histological and ultrastructural correlations in chronic gastritis. , 1979, The American journal of gastroenterology.
[16] J. H. Baron,et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. , 1995, Gut.
[17] J. Chan,et al. Pathologic changes of gastric mucosa colonized by Helicobacter pylori. , 1992, Human pathology.
[18] M. Blaser,et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. , 1991, The New England journal of medicine.
[19] J. Isenberg,et al. Duodenal bicarbonate secretion: eradication of Helicobacter pylori and duodenal structure and function in humans. , 1996, Gastroenterology.
[20] T. Hirohata. Mortality from gastric cancer and other causes after medical or surgical treatment for gastric ulcer. , 1968, Journal of the National Cancer Institute.
[21] S. Badve,et al. Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects. , 1995, Gut.
[22] K. Jaskiewicz,et al. Long‐term histologic consequences of suppression/eradication of Helicobacter pylori in antral mucosa , 1993 .
[23] Alter Mj,et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. , 1991, BMJ.
[24] N. Harpaz,et al. Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori. , 1994, The American journal of gastroenterology.
[25] M. O'brien,et al. Early gastric cancer. Clinicopathologic study. , 1985, The American journal of medicine.
[26] M. Blaser,et al. Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production , 1993, Infection and immunity.
[27] S. Meuwissen,et al. Hypertrophic protein-losing gastropathy. A retrospective analysis of 40 cases in The Netherlands. The Dutch Ménétrier Study Group. , 1992, Scandinavian journal of gastroenterology. Supplement.
[28] A. Lee,et al. The importance of local acid production in the distribution of Helicobacter felis in the mouse stomach. , 1995, Gastroenterology.
[29] M. Mravunac,et al. Improvement of gastric inflammation and resolution of epithelial damage one year after eradication of Helicobacter pylori. , 1995, Journal of clinical pathology.
[30] A. Lilienfeld,et al. MODEL FOR GASTRIC CANCER EPIDEMIOLOGY , 1976, The Lancet.
[31] R. Negrini,et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. , 1996, Gastroenterology.
[32] P. Sipponen,et al. Long-term effect of vagotomy on gastric mucosa and Helicobacter pylori in duodenal ulcer patients. , 1991, Scandinavian journal of gastroenterology. Supplement.
[33] K. Geboes. Histological classification of chronic gastritis: an iconoclastic view. , 1992, Gastroenterology.
[34] L. P. Andersen,et al. Investigation of Helicobacter pylori ascorbic acid oxidating activity. , 1995, FEMS immunology and medical microbiology.
[35] A. Blum,et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. , 1995, Gut.
[36] M. Blaser,et al. Mosaicism in Vacuolating Cytotoxin Alleles of Helicobacter pylori , 1995, The Journal of Biological Chemistry.
[37] G. Porro,et al. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. , 1994, Scandinavian journal of gastroenterology. Supplement.
[38] G. Adams,et al. Distribution of Helicobacter pylori colonisation and associated gastric inflammatory changes: difference between patients with duodenal and gastric ulcers. , 1993, Journal of clinical pathology.
[39] S. Sarna,et al. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori , 1992, The Lancet.
[40] M. Dixon,et al. Observer variation in the assessment of chronic gastritis according to the Sydney system , 1994, Histopathology.
[41] R. Negrini,et al. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa. , 1991, Gastroenterology.
[42] M. Murakami,et al. Mechanism of Helicobacter pylori-associated gastric mucosal injury. , 1995, Digestive diseases and sciences.
[43] M. Blaser,et al. Helicobacter pylori and gastric acid: biological and therapeutic implications. , 1996, Gastroenterology.
[44] R. G. Norfleet,et al. Strange bedfellows: duodenal ulcer and cancer of the stomach. , 1989, Journal of clinical gastroenterology.
[45] N. Figura. Mouth-to-mouth resuscitation and Helicobacter pylori infection , 1996, The Lancet.
[46] D. Graham,et al. Iatrogenic Campylobacter pylori infection is a cause of epidemic achlorhydria. , 1988, The American journal of gastroenterology.
[47] D. Taylor,et al. Construction of a Helicobacter pylori genome map and demonstration of diversity at the genome level , 1992, Journal of bacteriology.
[48] J. Fox,et al. Helicobacter mustelae-induced gastritis and elevated gastric pH in the ferret (Mustela putorius furo) , 1991, Infection and Immunity.
[49] P. Navaratnam,et al. Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy. , 1996, European journal of gastroenterology & hepatology.
[50] M. Blaser,et al. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. , 1995, Laboratory investigation; a journal of technical methods and pathology.
[51] M. Blaser,et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. , 1995, Cancer research.
[52] A. Axon,et al. Ascorbic acid in the human stomach. , 1989, Gastroenterology.
[53] P. Amy,et al. Helicobacter pylori comb. nov. Exhibits Facultative Acidophilism and Obligate Microaerophilism , 1994, Applied and environmental microbiology.
[54] G. Friedman,et al. Helicobacter pylori infection and the risk of gastric carcinoma. , 1991, The New England journal of medicine.
[55] L. Olbe,et al. The influence of Helicobacter pylori infection on postprandial duodenal acid load and duodenal bulb pH in humans. , 1996, Gastroenterology.
[56] A. Berstad,et al. A histological study of gastric mucosa before and after proximal gastric vagotomy in duodenal ulcer patients. , 1975, Scandinavian journal of gastroenterology.
[57] G. Pals,et al. Clinical significance of pepsinogen a isozymogens, serum pepsinogen A and C levels, and serum gastrin levels , 1987, Cancer.
[58] R. Genta. Recognizing atrophy: another step toward a classification of gastritis. , 1996, The American journal of surgical pathology.
[59] J. Crabtree,et al. Helicobacter pylori and gastric mucosal cytokines: evidence that CagA-positive strains are more virulent. , 1995, Laboratory investigation; a journal of technical methods and pathology.
[60] P. Correa,et al. Grading and classification of chronic gastritis: one American response to the Sydney system. , 1992, Gastroenterology.
[61] J. Fraumeni,et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. , 1992, Journal of the National Cancer Institute.
[62] E. Quigley,et al. Peptic ulcer and cancer: an examination of the relationship between chronic peptic ulcer and gastric carcinoma. , 1987, Scandinavian journal of gastroenterology.
[63] C. Caygill,et al. Increased risk of cancer mortality after vagotomy for peptic ulcer: a preliminary analysis. , 1991, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[64] R. Whitehead. The classification of chronic gastritis: current status. , 1995, Journal of clinical gastroenterology.
[65] D. Graham,et al. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. , 1993, Scandinavian journal of gastroenterology.
[66] F. Mégraud,et al. Laboratory-acquired Helicobacter pylori infection , 1995, The Lancet.
[67] P. Sipponen,et al. The Sydney System: Epidemiology and natural history of chronic gastritis , 1991, Journal of Gastroenterology and Hepatology.
[68] R. Hunt,et al. Epidemic hypochlorhydria. , 1985, British medical journal.
[69] D. Cave,et al. EFFECT OF A CAMPYLOBACTER PYLORI PROTEIN ON ACID SECRETION BY PARIETAL CELLS , 1989, The Lancet.
[70] M. Blaser,et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. , 1989, The New England journal of medicine.
[71] K. McColl,et al. Effect of Helicobacter pylori and its eradication on gastric juice ascorbic acid. , 1994, Gut.
[72] A. Blum,et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. , 1996, Gastroenterology.
[73] R. Rappuoli,et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[74] A. Axon,et al. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. , 1991, Gut.
[75] D. Taylor,et al. Helicobacter pylori expresses a complex surface carbohydrate, Lewis X , 1995, Infection and immunity.
[76] G. Bodemar,et al. Histologic changes in the gastroduodenal mucosa after long-term medical treatment with cimetidine or parietal cell vagotomy in patients with juxtapyloric ulcer disease. , 1988, Scandinavian journal of gastroenterology.
[77] K. Kimura,et al. A topographical relationship between Helicobacter pylori and gastritis: quantitative assessment of Helicobacter pylori in the gastric mucosa. , 1991, The American journal of gastroenterology.
[78] M. Bugnoli,et al. Serologic IgG recognition of Helicobacter pylori cytotoxin‐associated protein, peptic ulcer and gastroduodenal pathology in childhood , 1993 .
[79] M. Fujishima,et al. Risk of gastric cancer in patients with non-surgically treated peptic ulcer. , 1990, Scandinavian journal of gastroenterology.
[80] P. Sipponen,et al. A 12-year follow-up study of chronic gastritis and Helicobacter pylori in a population-based random sample. , 1995, Scandinavian journal of gastroenterology.
[81] E. Fontham,et al. Antral atrophy, Helicobacter pylori colonization, and gastric pH. , 1996, American journal of clinical pathology.
[82] E. Fontham,et al. Gastric precancerous process in a high risk population: cross-sectional studies. , 1990, Cancer research.
[83] P. Blok,et al. Intestinal metaplasia and Helicobacter pylori: an endoscopic bioptic study of the gastric antrum. , 1992, Gut.
[84] G. Nicholson,et al. Distribution of Campylobacter pylori in the human stomach obtained at postmortem. , 1988, Scandinavian journal of gastroenterology.
[85] R. Uibo,et al. Seven-year follow-up study of chronic gastritis in gastric ulcer patients. , 1985, Scandinavian journal of gastroenterology.
[86] D. Graham,et al. Helicobacter pylori Infection: Genetic and Environmental Influences: A Study of Twins , 1994, Annals of Internal Medicine.
[87] H. Møller,et al. Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users. , 1992, Gut.
[88] A. Karameris,et al. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. , 1995, Gastrointestinal endoscopy.
[89] S. Ichiyama,et al. Interleukin-8 activity correlates with histological severity in Helicobacter pylori-associated antral gastritis. , 1996, The American journal of gastroenterology.
[90] H. Zanen,et al. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. , 1988, Gastroenterology.
[91] D. Graham,et al. Changes in the gastric mucosa following eradication of Helicobacter pylori. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[92] N. Figura. Helicobacter pylori exotoxins and gastroduodenal diseases associated with cytotoxic strain infection. , 1996, Alimentary pharmacology & therapeutics.
[93] G. Nicholson,et al. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. , 1987, The American journal of gastroenterology.
[94] R. Berrelkamp,et al. Serology to monitor the efficacy of anti-Helicobacter pylori treatment , 1994 .
[95] P. Malfertheiner,et al. Helicobacter pylori and Gastroduodenal Pathology , 1993, Springer Berlin Heidelberg.
[96] A. Lee,et al. The development of atrophic gastritis—Helicobacter pylori and the effects of acid suppressive therapy , 1995, Alimentary pharmacology & therapeutics.
[97] E. Kuipers,et al. The prevalence of Helicobacter pylori in peptic ulcer disease. , 1995, Alimentary pharmacology & therapeutics.
[98] M. Tatsuta,et al. Location, healing, and recurrence of gastric ulcers in relation to fundal gastritis. , 1975, Gastroenterology.
[99] B. Marshall,et al. Attempt to fulfil Koch's postulates for pyloric Campylobacter , 1985, The Medical journal of Australia.
[100] F. Mégraud,et al. Further evidence of the toxic effect of ammonia produced by Helicobacter pylori urease on human epithelial cells , 1992, Infection and immunity.
[101] L. Turnberg,et al. pH of the microclimate lining human gastric and duodenal mucosa in vivo. Studies in control subjects and in duodenal ulcer patients. , 1987, Gastroenterology.
[102] N. Muñoz,et al. Intestinal metaplasia types and the risk of gastric cancer: A cohort study in Slovenia , 1994, International journal of cancer.
[103] W. Creutzfeldt,et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. , 1993, Gastroenterology.
[104] Douglas K Owens,et al. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials , 1996, The Lancet.
[105] Y. Fukuda. Suppression of Helicobacter pylori colonization with omeprazole. , 1996, Scandinavian Journal of Gastroenterology, Supplement.
[106] A. Labigne,et al. Helicobacter pylori requires an acidic environment to survive in the presence of urea , 1995, Infection and immunity.
[107] E. Kuipers,et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. , 1995, The American journal of gastroenterology.
[108] P. Sipponen,et al. Disappearance of gastritis after eradication of Helicobacter pylori. A morphometric study. , 1991, Scandinavian journal of gastroenterology.
[109] S. Curley,et al. Association of gastric adenocarcinoma with the HLA class II gene DQB10301. , 1996, Gastroenterology.
[110] G. R. Davies,et al. Relationship between infective load of Helicobacter pylori and reactive oxygen metabolite production in antral mucosa. , 1994, Scandinavian journal of gastroenterology.
[111] H. Endtz,et al. Long term serological surveillance after treatment of Helicobacter pylori infection. , 1991, Gut.
[112] Q. Jiang,et al. Variability of gene order in different Helicobacter pylori strains contributes to genome diversity , 1996, Molecular microbiology.
[113] D. Graham,et al. Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. , 1993, Human pathology.
[114] E. Fontham,et al. Gastric precancerous process in a high risk population: cohort follow-up. , 1990, Cancer research.
[115] M. Blaser,et al. Mutation of the cytotoxin-associated cagA gene does not affect the vacuolating cytotoxin activity of Helicobacter pylori , 1994, Infection and immunity.
[116] R. Uibo,et al. Chronic gastritis: progression of inflammation and atrophy in a six-year endoscopic follow-up of a random sample of 142 Estonian urban subjects. , 1991, Scandinavian journal of gastroenterology. Supplement.
[117] E. El-Omar,et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. , 1995, Gastroenterology.
[118] B. Rathbone,et al. Immune response of the gastric mucosa to Campylobacter pylori. , 1988, Scandinavian journal of gastroenterology. Supplement.
[119] R. V. D. van der Hulst,et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. , 1996, The Journal of infectious diseases.
[120] D. McGee,et al. Gastric intestinal metaplasia in ethnic groups in the southwestern United States. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[121] G. Tytgat. The Sydney System: Endoscopic division. Endoscopic appearances in gastritis/duodenitis , 1991, Journal of gastroenterology and hepatology.
[122] M. Stolte,et al. Helicobacter pylori eradication in the treatment and differential diagnosis of giant folds in the corpus and fundus of the stomach. , 1995, Zeitschrift fur Gastroenterologie.
[123] R. Fiocca,et al. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. , 1992, Digestion.
[124] A. Oshima,et al. Fundal atrophic gastritis as a risk factor for gastric cancer , 1993, International journal of cancer.
[125] P. Sipponen,et al. The sequelae and course of chronic gastritis during a 30- to 34-year bioptic follow-up study. , 1985, Scandinavian journal of gastroenterology.
[126] A. Price. The Sydney System: Histological division , 1991, Journal of gastroenterology and hepatology.
[127] P. Sistonen,et al. Classification principles and genetics of chronic gastritis. , 1987, Scandinavian journal of gastroenterology. Supplement.
[128] D. Tompkins,et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology , 1991, The Lancet.
[129] J. Mclaughlin,et al. Gastric cancer risk after vagotomy. , 1994, Gut.
[130] Y. Matsuzawa,et al. Improved fold width and increased acid secretion after eradication of the organism in Helicobacter pylori associated enlarged fold gastritis. , 1994, Gut.
[131] R. Gilman,et al. Helicobacter pylori and progressive gastric pathology that predisposes to gastric cancer. , 1991, Scandinavian journal of gastroenterology. Supplement.
[132] N. Shepherd,et al. Histological assessment of the Sydney classification of endoscopic gastritis. , 1994, Gut.
[133] J. Parsonnet. Helicobacter pylori and gastric cancer. , 1993, Gastroenterology clinics of North America.
[134] E. Kuipers,et al. Helicobacter pylori and atrophic gastritis: importance of the cagA status. , 1996, Journal of the National Cancer Institute.
[135] D. Beall. Classification and Grading of Gastritis: The Updated Sydney System , 1997 .
[136] T. Borody,et al. Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori. , 1993, The American journal of gastroenterology.
[137] J. Schrager,et al. The antrum in patients with duodenal and gastric ulcers. , 1967, Gut.
[138] M. Blaser,et al. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa , 1992, The Journal of experimental medicine.
[139] H. Adami,et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. , 1996, The New England journal of medicine.
[140] J. Tjandra,et al. Helicobacter pylori in peptic ulcer disease. , 1995, The Australian and New Zealand journal of surgery.